NMN Clinical Trials in Humans: What the Research Actually Shows

NMN has moved well beyond the laboratory. β-Nicotinamide mononucleotide (β-NMN) has now been evaluated in more than 15 published randomized controlled trials in people, plus pharmacokinetic and safety studies. Here is what those studies actually tested, what they found, and why the details — molecule, dose, purity and documentation — matter when you choose an NMN supplement.

What is β-NMN?

β-NMN is a nucleotide the body uses to make NAD+ (nicotinamide adenine dinucleotide), a coenzyme involved in cellular energy metabolism. NAD+ levels decline with age, which is why researchers began asking whether supplying its direct precursor could raise them. The "β" refers to the specific molecular form that is biologically active and that human trials have studied.

What human research has studied

Published human trials of oral β-NMN have enrolled healthy adults, older adults, recreational runners and people with prediabetes. In repeated-dose trials of standard β-NMN, daily intakes have ranged from 250 mg to 1,250 mg, with durations up to 24 weeks. Most were randomized, double-blind and placebo-controlled — the design that gives the most reliable answers.

The clearest finding: oral β-NMN raises NAD+

The most consistent result across trials is biochemical. In randomized, placebo-controlled studies, daily oral β-NMN significantly increased blood NAD+:

• At 250 mg/day, whole-blood NAD+ rose significantly within four weeks and stayed elevated through 12 weeks, then returned to baseline after supplementation stopped (Okabe et al., 2022).
• In a dose-ranging trial of 300, 600 and 900 mg/day, blood NAD+ rose at every dose, with 600 mg producing a larger increase than 300 mg (Yi et al., 2023).
• At 1,000 mg/day, whole-blood NAD+ roughly doubled within 14 days compared with placebo in a 2026 randomized trial (Christen et al., Nature Metabolism, 2026).

What happened beyond NAD+

Functional results are promising and still developing. Trials have reported improved skeletal-muscle insulin sensitivity in women with prediabetes (Yoshino et al., 2021), better six-minute walking distance and well-being scores (Yi et al., 2023), faster walking speed in older adults (Igarashi et al., 2022; Morifuji et al., 2024) and improved aerobic capacity at the ventilatory threshold in runners (Liao et al., 2021).

Not every trial found an effect on its main outcome, and that matters too. Studies of arterial stiffness, of physical performance in older adults with diabetes, and of a lower 300 mg dose did not find statistically significant differences from placebo, and pooled analyses show no consistent change in blood glucose or cholesterol. On safety, a 2026 meta-analysis of placebo-controlled trials found that NMN did not increase adverse events compared with placebo (Yang et al., 2026).

The molecule versus the manufacturer

Every trial used β-NMN from a particular supplier, and good science identifies each study by its own materials. But the compound investigated is the same molecule: β-nicotinamide mononucleotide. The evidence describes what that molecule did at a given dose, form and duration. That is why molecular identity and purity are the first things to check in any NMN product: the research is relevant to a supplement only to the extent the supplement actually delivers β-NMN, at a meaningful dose.

Why dose, purity and identity matter

Dose: repeated-dose trials of standard β-NMN have used 250–1,250 mg per day, and NAD+ responses were larger at 600 mg than at 300 mg in a dose-ranging study. Purity: an NMN product is only as good as the β-NMN it contains, which is measured analytically — typically by HPLC — on a certificate of analysis. Identity: the label should name β-NMN specifically, and the documentation should connect the ingredient batch to the product you buy.

What the evidence says about delivery

Conventional oral β-NMN has increased blood NAD+ in human clinical trials. Ordinary 125 mg tablets raised whole-blood NAD+ versus placebo (Okabe et al., 2022), and standard 150 mg capsules raised blood NAD+ at every dose tested and improved six-minute walking distance versus placebo (Yi et al., 2023). None of these trials used delayed-release, enteric-coated or targeted-delivery technology, and we found no published human head-to-head study showing that such technologies raise NAD+ more than conventional oral β-NMN.

Capsule material is a separate question. Hypromellose (HPMC) is an established plant-based material for oral pharmaceutical and supplement capsules, and in a human comparative study HPMC and gelatin capsules performed comparably for the formulation tested — a model drug, not NMN (Cole et al., 2004).

How Novera applies this

Novera NMN 30,000 provides 1,000 mg of β-NMN per daily serving — a daily amount that has itself been evaluated in published human research — in vegan HPMC capsules made in Japan. Novera lot 04.2029/NV101 was manufactured using BONTAC® β-NMN batch BT05L125B011, whose raw-material certificate of analysis documents 99.9% purity by HPLC. Independent studies used their own study materials; none tested Novera. What we can show you is exactly what is in each batch: the finished-product certificate, the BONTAC® raw-material certificate and the facility documentation, published openly.

Explore every study — dose, duration, findings and limitations — in our NMN human research library, then follow the documentation for your Novera batch.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.